TABLE 3.
Incidence of grade 3 or 4 laboratory abnormalities during treatment and treatment-free follow-up
| Parametera | No. of patients (%)
|
P valueb | |
|---|---|---|---|
| FTC+CLV (n = 82) | FTC (n = 81) | ||
| Treatment period, day 0 to wk 24 | |||
| At least 1 grade 3 or 4 laboratory abnormality | 18 (22) | 13 (16) | NS |
| ALT | 6 (7) | 5 (6) | NS |
| AST | 6 (7) | 2 (2) | NS |
| Creatine kinase | 6 (7) | 2 (2) | NS |
| Glucose | 3 (4) | 1 (1) | NS |
| Amylase | 2 (2) | 1 (1) | NS |
| Lipase | 1 (1) | 5 (6) | NS |
| Treatment-free follow-up, wk 24 to 48 | |||
| At least 1 grade 3 or 4 laboratory abnormality | 9 (11) | 22 (28) | 0.009 |
| ALT | 4 (5) | 13 (16) | 0.022 |
| AST | 3 (4) | 10 (13) | 0.046 |
| Creatine kinase | 3 (4) | 4 (5) | NS |
| Glucose | 2 (2) | 2 (3) | NS |
| Amylase | 0 (0) | 5 (6) | 0.028 |
| Lipase | 0 (0) | 3 (4) | NS |
a
More than one patient.
b
NS indicates a P level of >0.05.